arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nexalin Technology, Inc.

NXL
$4.71 ▲ +0.21 (+4.67%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
23 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nexalin Technology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $99.6M
Dividend Yield
Revenue Growth -82.8%
Op. Margin None
ROIC -116.8%
FCF / Share $-0.09
Trailing P/E
Price / Book 68.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.16K
↓ -82.8%
Net Income Profit after all expenses
$-2.24M
↓ -41.6%
Operating Margin Operating profit as % of sales
-53.8%
↑ +50.0%
FCF / Share Free cash flow per share
$-0.09
↑ +1.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Financial Health
5
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters